Progress in research on the novel cancer therapeutic target Cdc20
10.16438/j.0513-4870.2017-0352
- VernacularTitle:新型肿瘤治疗靶点Cdc20的研究进展
- Author:
Xiang-yang LE
1
;
Meng-ni KUAI
1
;
Qian-bin LI
1
;
Zhuo CHEN
1
Author Information
1. XiangYa School of Pharmaceutical Sciences, Central South University, Changsha 410013, China
- Publication Type:REVIEWS
- Keywords:
cancer;
cell division cycle protein 20;
E3 ubiquitin ligase;
inhibitor
- From:
Acta Pharmaceutica Sinica
2017;52(9):1366-1371
- CountryChina
- Language:Chinese
-
Abstract:
The anaphase promoting complex (APC) regulates cell cycle progression by forming two functionally distinct E3 ubiquitin ligase complexes, APCCdc20 activated by cell division cycle protein 20 (Cdc20) and APCCdh1 activated by Cdc20 homologue 1 (Cdh1), respectively. Cdc20 and Cdh1 have different functions in the occurrence and development of the tumor. Cdc20 is a cancer promoter while Cdh1 suppresses tumorigenesis. Emerging evidence has begun to reveal that Cdc20 has positive functions in tumorigenesis, the overexpression of Cdc20 has been observed in many cancers. Currently, Cdc20 inhibitors, mostly non-specific inhibitors except apcin, not only block the combination between Cdc20 and APC, also block the combination between Cdh1 and APC, which leads to a poor selectivity. In this paper, the Cdc20 role in the development and process of cancers and its inhibitors are reviewed.
